FDA approves GSK’s Hibsago for chronic hepatitis B
Bitget2026/10/20 20:26- FDA approved GSK’s Hibsago (bepirovirsen) for chronic hepatitis B in eligible adults without cirrhosis.
- The six-month treatment is used with nucleos(t)ide analogue therapy, with self-administration available following the first dose.
- Phase III trials showed a 19% functional cure rate versus 0% with placebo in patients with HBsAg levels ≤3,000 IU/ml.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Starbucks (SBUX.US) Q4 U.S. business recovers beyond expectations, new fiscal year growth guidance slows to 4%
Starbucks reported Q4 revenue of $9.14 billion, falling short of expectations. Same-store sales in the U.S. rose by 7.7%. Adjusted EPS was $0.80, exceeding forecasts.
Report: ECB officials tend to favor a rate hike in December, with inflation outlook being the key variable
According to media reports, officials from the European Central Bank generally believe that, based on current data and the economic impact of the Middle East war, if the inflation situation does not improve, the European Central Bank will raise interest rates by 25 basis points in December. Currently, the market is pricing an 85% probability of a 25 basis point rate hike by the ECB in December. Analysts note that although the ECB has left room for another rate increase in December, the Governing Council is laying the groundwork to end the current tightening cycle.
Crypto prices
More
